Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

LIRA-ADD2SGLT2i - Liraglutide Versus Placebo as add-on to SGLT2 Inhibitors.

ClinicalTrials.gov ID: NCT02964247

Public ClinicalTrials.gov record NCT02964247. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 1:14 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

LIRA-ADD2SGLT2i - Liraglutide Versus Placebo as add-on to SGLT2 Inhibitors

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The trial is conducted in Asia, Europe, North America and South America. The aim of the study is to compare the effect of liraglutide 1.8 mg/day versus placebo as add-on to an SGLT2 inhibitor with or without metformin on glycaemic control in subjects with type 2 diabetes mellitus.

Study identification

NCT ID
NCT02964247
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Novo Nordisk A/S
Industry
Enrollment
303 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Mar 3, 2017 (Actual)
Primary completion
May 4, 2018 (Actual)
Completion
May 8, 2018 (Actual)
Last update posted
Nov 17, 2020

2017 – 2018

United States locations

U.S. sites
56
U.S. states
21
U.S. cities
50
Facility City State ZIP Site status
Novo Nordisk Investigational Site Birmingham Alabama 35294 —
Novo Nordisk Investigational Site Montgomery Alabama 36109 —
Novo Nordisk Investigational Site Tucson Arizona 85741 —
Novo Nordisk Investigational Site Lancaster California 93534 —
Novo Nordisk Investigational Site Northridge California 91325 —
Novo Nordisk Investigational Site Sacramento California 95821 —
Novo Nordisk Investigational Site San Diego California 92111 —
Novo Nordisk Investigational Site San Ramon California 94583 —
Novo Nordisk Investigational Site Vista California 92083 —
Novo Nordisk Investigational Site Gainesville Florida 32653 —
Novo Nordisk Investigational Site Hollywood Florida 33024 —
Novo Nordisk Investigational Site Jacksonville Florida 32216 —
Novo Nordisk Investigational Site Jacksonville Florida 32256 —
Novo Nordisk Investigational Site Jacksonville Florida 32258 —
Novo Nordisk Investigational Site Maitland Florida 32751 —
Novo Nordisk Investigational Site Miami Florida 33165 —
Novo Nordisk Investigational Site Miami Florida 33176 —
Novo Nordisk Investigational Site Miami Lakes Florida 33016 —
Novo Nordisk Investigational Site Tampa Florida 33606 —
Novo Nordisk Investigational Site Lawrenceville Georgia 30046 —
Novo Nordisk Investigational Site Roswell Georgia 30076 —
Novo Nordisk Investigational Site Statesboro Georgia 30461 —
Novo Nordisk Investigational Site Blackfoot Idaho 83221 —
Novo Nordisk Investigational Site Evansville Indiana 47714 —
Novo Nordisk Investigational Site Topeka Kansas 66606 —
Novo Nordisk Investigational Site Lexington Kentucky 40503 —
Novo Nordisk Investigational Site New Orleans Louisiana 70115 —
Novo Nordisk Investigational Site Kalamazoo Michigan 49009 —
Novo Nordisk Investigational Site Rochester Michigan 48307 —
Novo Nordisk Investigational Site Billings Montana 59101 —
Novo Nordisk Investigational Site Henderson Nevada 89052-2649 —
Novo Nordisk Investigational Site Albany New York 12203 —
Novo Nordisk Investigational Site West Seneca New York 14224 —
Novo Nordisk Investigational Site Charlotte North Carolina 28210 —
Novo Nordisk Investigational Site Charlotte North Carolina 28226 —
Novo Nordisk Investigational Site Charlotte North Carolina 28277 —
Novo Nordisk Investigational Site Kinston North Carolina 28501 —
Novo Nordisk Investigational Site Wilmington North Carolina 28401 —
Novo Nordisk Investigational Site Cincinnati Ohio 45245 —
Novo Nordisk Investigational Site Columbus Ohio 43212 —
Novo Nordisk Investigational Site McMurray Pennsylvania 15317 —
Novo Nordisk Investigational Site Pittsburgh Pennsylvania 15243 —
Novo Nordisk Investigational Site Moncks Corner South Carolina 29461 —
Novo Nordisk Investigational Site Mt. Pleasant South Carolina 29464 —
Novo Nordisk Investigational Site Myrtle Beach South Carolina 29572 —
Novo Nordisk Investigational Site Spartanburg South Carolina 29303 —
Novo Nordisk Investigational Site Memphis Tennessee 38119 —
Novo Nordisk Investigational Site Nashville Tennessee 37203 —
Novo Nordisk Investigational Site Dallas Texas 75231 —
Novo Nordisk Investigational Site Edinburg Texas 78539 —
Novo Nordisk Investigational Site Houston Texas 77024 —
Novo Nordisk Investigational Site Houston Texas 77030 —
Novo Nordisk Investigational Site Humble Texas 77338 —
Novo Nordisk Investigational Site Round Rock Texas 78681 —
Novo Nordisk Investigational Site Schertz Texas 78154 —
Novo Nordisk Investigational Site Spokane Washington 99201 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 26 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02964247, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Nov 17, 2020 · Synced Oct 25, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT02964247 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →